Page 334 - medicina-integrativa_compress

330 PARTE II, SECCIÓN 4 ENFERMEDADES CARDIOVASCULARES

mechanisms. The Task Force of the Working Group on 30. Lemaitre RN, King IB, Raghunathan TE, et al: Cell membrane
Arrhythmias of the European Society of Cardiology. Eur Heart J trans-fatty acids and the risk of primary cardiac arrest. Circulation
12:1112-1131, 1991. 105:697-701, 2002.
9. Pratt CM, Camm AJ, Cooper W, et al: Mortality in the Survival 31. Leaf A, Xiao YF, Kang JX, et al: Prevention of sudden cardiac
With ORal D-sotalol (SWORD) trial: Why did patients die? Am J death by omega-3 polyunsaturated fatty acids. Pharmacol Ther
Cardiol 81:869-876, 1998. 98:355-377, 2003.
10. Julian DG, Camm AJ, Frangin G, et al: Randomised trial of effect of 32. Renaud S, Lanzmann-Petithory D: Dietary fats and coronary heart
amiodarone on mortality in patients with left-ventricular dysfunction disease pathogenesis. Curr Atheroscler Rep 4:419-424, 2002.
after recent myocardial infarction: EMIAT. European Myocardial 33. Lehr D: A possible beneficial effect of selenium administration in
Infarct Amiodarone Trial Investigators. Lancet 349:667-674, 1997. antiarrhythmic therapy. J Am Coll Nutr 13:496-498, 1994.
11. Cairns JA, Connelly SJ, Roberts R, Gent M: Randomised trial of 34. Lumme JA, Jounela AJ: The effect of potassium and potassium
outcome after myocardial infarction in patients with frequent or plus magnesium supplementation on ventricular extrasystoles in
repetitive ventricular premature depolarisations: CAMIAT. mild hypertensives treated with hydrochlorothiazide. Int J Cardiol
Canadian Amiodarone Myocardial Infarction Arrhythmia Trial 25:93-97, 1989.
Investigators. Lancet 349:675-682, 1997. 35. Tsuji H, Venditti FJ Jr, Evans JC, et al: The associations of levels
12. Janse MJ, Malik M, Camm AJ, et al: Identification of post acute of serum potassium and magnesium with ventricular premature
myocardial infarction patients with potential benefit from complexes. The Framingham Heart Study. Am J Cardiol 74:
prophylactic treatment with amiodarone. A substudy of EMIAT 232-235, 1994.
(the European Myocardial Infarct Amiodarone Trial). Eur Heart J 36. Spencer JC: Direct relationship between the body’s copper/zinc
19:85-95, 1998. ratio, ventricular premature beats, and sudden coronary death. Am J
13. Boutitie F, Boissel JP, Connelly SJ, et al: Amiodarone interaction Clin Nutr 32:1184-1185, 1979.
with beta-blockers: Analysis of the merged EMIAT (European 37. Hardarson T, Kristinsson A, Skuladottir G, et al: Cod liver oil does
Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian not reduce ventricular extrasystoles after myocardial infarction.
Amiodarone Myocardial Infarction Trial) databases. The EMIAT J Intern Med 226:33-37, 1989.
and CAMIAT Investigators. Circulation 99:2268-2275, 1999. 38. Bashir Y, Sneddon JF, Staunton HA, et al: Effects of long-term
14. Dobmeyer DJ, Stine RA Leier CV, et al: The arrhythmogenic effects oral magnesium chloride replacement in congestive heart failure
of caffeine in human beings. N Engl J Med 308:814-816, 1983. secondary to coronary artery disease. Am J Cardiol 72:1156-1162,
15. Donnerstein RL, Zhu D, Samson R, et al: Acute effects of caffeine 1993.
ingestion on signal-averaged electrocardiograms. Am Heart J 39. Mehta A, Jain AC, Mehta MC, Billie M: Caffeine and cardiac
136:643-646, 1998. arrhythmias: An experimental study in dogs with review of
16. Rosano GM, Rillo M, Leonardo F, et al: Palpitations: What is the literature. Acta Cardiol 52:273-283, 1997.
mechanism, and when should we treat them? Int J Fertil Womens 40. Chou T: Wake up and smell the coffee: Caffeine, coffee, and the
Med 42:94-100, 1997. medical consequences. West J Med 157:544-553, 1992.
17. Barsky AJ, Delamater BA, Clancy SA, et al: Somatized psychiatric 41. Myers MG, Harris L: High-dose caffeine and ventricular
disorder presenting as palpitations. Arch Intern Med 156: arrhythmias. Can J Cardiol 6:95-98, 1990.
1102-1108, 1996. 42. Haller CA, Benowitz NL: Adverse cardiovascular and central
18. Barsky AJ, Cleary PD, Coeytaux RR, Ruskin JN: Psychiatric nervous system events associated with dietary supplements
disorders in medical outpatients complaining of palpitations. containing ephedra alkaloids. N Engl J Med 343:1833-1838,
J Gen Intern Med 9:306-313, 1994. 2000.
19. Weber BE, Kapoor WN: Evaluation and outcomes of patients with 43. Shen WK, Low PA, Jahangir A, et al: Is sinus node modification
palpitations. Am J Med 100:138-148, 1996. appropriate for inappropriate sinus tachycardia with features of
20. Lok NS, Lau CP: Prevalence of palpitations, cardiac arrhythmias postural orthostatic tachycardia syndrome? Pacing Clin
and their associated risk factors in ambulant elderly. Int J Cardiol Electrophysiol 24:217-230, 2001.
54:231-236, 1996. 44. Lochen ML: The Tromso Study: associations between self-reported
21. Zeldis SM, Levine BJ, Michelson EL, Morganroth J: Cardiovascular arrhythmia, psychological conditions, and lifestyle. Scand J Prim
complaints: Correlation with cardiac arrhythmias on 24-hour Health Care 9:265-270, 1991.
electrocardiographic monitoring. Chest 78:456-461, 1980. 45. Hinkle LE Jr, Thaler HT, Merke DP, et al: The risk factors for
22. Crawford MH, Bernstein SJ, Deedwania PC, et al: ACC/AHA arrhythmic death in a sample of men followed for 20 years.
guidelines for ambulatory electrocardiography: Executive summary Am J Epidemiol 127:500-515, 1988.
and recommendations. A report of the American College of 46. Albert CM, Manson JF, Cook NR, et al: Moderate alcohol
Cardiology/American Heart Association task force on practice consumption and the risk of sudden cardiac death among
guidelines (committee to revise the guidelines for ambulatory US male physicians. Circulation 100:944-950, 1999.
electrocardiography). Circulation 100:886-893, 1999. 47. McCarty MF: Fish oil may be an antidote for the cardiovascular
23. Zimetbaum PJ, Josephson ME: The evolving role of ambulatory risk of smoking. Med Hypotheses 46:337-347, 1996.
arrhythmia monitoring in general clinical practice. Ann Intern 48. Alexander CN, Orme-Johnson DW, Schneider RH, Walton KG:
Med 130:848-856, 1999. Effects of transcendental meditation compared to other methods
24. Antman EM, Ludmer PL, McGowan N, et al: Transtelephonic of relaxation and meditation in reducing risk factors, morbidity,
electrocardiographic transmission for management of cardiac and mortality. Homeostasis 35:243-264, 1994.
arrhythmias. Am J Cardiol 58:1021-1024, 1986. 49. Zamarra JW, Scheider RH, Besseghini I, et al: Usefulness of the
25. Chadda KD, Harrington D, Kushnik H, Bodenheimer MM: transcendental meditation program in the treatment of patients
The impact of transtelephonic documentation of arrhythmia on with coronary artery disease. Am J Cardiol 77:867-870, 1996.
morbidity and mortality rate in sudden death survivors. Am Heart J 50. Weiss T: Biofeedback training for cardiovascular dysfunctions.
112:1159-1165, 1986. Med Clin North Am 61:913-928, 1977.
26. Krahn AD, Klein GJ, Yee R, Skanes AC: Randomized assessment 51. Johnston D: Clinical applications of biofeedback. Br J Hosp Med
of syncope trial: conventional diagnostic testing versus a 20:561-566, 1978.
prolonged monitoring strategy. Circulation 104:46-51, 2001. 52. Silver BV, Blanchard EB. Biofeedback and relaxation training in the
27. Moss AJ, Hall WJ, Cannon DS, et al: Improved survival with an treatment of psychophysiological disorders: Or are the machines
implanted defibrillator in patients with coronary disease at high risk really necessary? J Behav Med 1:217-239, 1978.
for ventricular arrhythmia. Multicenter Automatic Defibrillator 53. Janssen K: Treatment of sinus tachycardia with heart-rate feedback.
Implantation Trial Investigators. N Engl J Med 335:1933-1940, 1996. J Behav Med 6:109-114, 1983.
28. Koskinen P, Kupari M, Leinonen H: Role of alcohol in recurrences 54. Vaitl D: [“One need not be a fakir or guru.” Biofeedback as an
of atrial fibrillation in persons less than 65 years of age. Am J interdisciplinary research technic]. Fortschr Med 102:541-544,
Cardiol 66:954-958, 1990. 1984.
29. Rigou DG, Pichel G, Fasah L: [Ventricular arrhythmia in young 55. Cowan MJ, Pike KC, Budzynski HK: Psychosocial nursing therapy
university students without evidence of heart disease]. Medicina following sudden cardiac arrest: Impact on two-year survival.
50:47-51, 1990. Nurs Res 50:68-76, 2001.